Latest revenue
$147.4M
as of 2026-03-31
Latest net income
$-2.5M
as of 2026-03-31
Net margin
-1.7%
as of 2026-03-31
Price · 5Y
Market data
Price feed temporarily unavailable for DFPH.
5-year trend
What this company does
Item 1. Business Overview Formed in 2007, the business of what is now The Oncology Institute, Inc. ("TOI", the "Company", "we", or "our) and its affiliated professional corporations was created initially as a collection of community oncology practices in southern California, and has evolved to be a national leader in the pursuit of reducing the ever-rising cost of oncology care, while embracing clinical best practices, state-of-the-art technology, and compassionate treatment of patients. While we continue our original purpose of seeing our patients on a fee-for-service basis for their oncology, hematology, specialty infusion, oral pharmacy needs, as well as enrolling patients in clinical…
AI summary unavailable — showing raw filing excerpt
Generated from DFPH's filing dated 2026-03-12
Key risks
Item 1A. Risk Factors We operate in a rapidly changing environment that involves a number of risks. Our operations and financial results are subject to various risks and uncertainties including those described below. You should consider carefully the risks and uncertainties described below, in addition to other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes, as well as our other public filings with the Securities and Exchange Commission. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material,…
AI summary unavailable — showing raw filing excerpt
Generated from DFPH's filing dated 2026-03-12
Profitability
Operating margin
-7.2%
53.0%Net margin
-12.1%
26.7%Return on equity
385.5%
121.4%Return on assets
-36.8%
1.7%Leverage
Debt / equity
-11.47×
124.3%Long-term debt / equity
-4.92×
119.0%Debt / assets
109.5%
11.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $147.4M | +41.2% | $-2.5M | +87.3% | -1.7% |
Q4 2025 2025-12-31 | $142.0M | +41.6% | $-7.5M | +43.0% | -5.3% |
Q3 2025 2025-09-30 | $136.6M | +36.7% | $-16.5M | -2.4% | -12.1% |
Q2 2025 2025-06-30 | $119.8M | +21.5% | $-17.0M | -9.9% | -14.2% |
Q1 2025 2025-03-31 | $104.4M | +10.3% | $-19.6M | +1.5% | -18.8% |
Q4 2024 2024-12-31 | $100.3M | — | $-13.2M | — | -13.1% |
Q3 2024 2024-09-30 | $99.9M | +21.8% | $-16.1M | +7.5% | -16.1% |
Q2 2024 2024-06-30 | $98.6M | +22.9% | $-15.5M | +8.4% | -15.7% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Offices & Clinics of Doctors of Medicine · SIC 8011
Your notes
Keep private notes on DFPH — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$2.3M
Insider selling
$29.3M
Net activity
−$27.1M
Distinct insiders
6
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns DFPH
No institutional holdings on file for DFPH yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once DFPH's latest filing finishes processing.